Drugs / Ottuzumab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06682130 Background | Nov 2024 → Nov 2027 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ottuzumab | “Ottuzumab introvenous infusion, 1000mg day1;” NCT06682130 ↗ |
| Route | Intravenous | “Ottuzumab introvenous infusion, 1000mg day1;” NCT06682130 ↗ |